Drug: Panitumumab (Vectibix, Amgen)
Status: Approved for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) as first-line therapy in combination with FOLFOX (oxaliplatin with fluorouracil and folinic acid) and as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin and irinotecan–containing chemotherapy.
Significant Information:
- First